BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...January 2019 as part of Frazier Healthcare Partners’ company creation activities. In August, Frazier led Lassen Therapeutics’...
...Lassen has at least one other preclinical program, LASN02; details are not disclosed. COMPANY PROFILE Lassen Therapeutics...
...receptor PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor Frazier Healthcare Partners Interleukin-11 (IL-11) receptor Lassen Therapeutics...
Items per page:
1 - 1 of 1
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...January 2019 as part of Frazier Healthcare Partners’ company creation activities. In August, Frazier led Lassen Therapeutics’...
...Lassen has at least one other preclinical program, LASN02; details are not disclosed. COMPANY PROFILE Lassen Therapeutics...
...receptor PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor Frazier Healthcare Partners Interleukin-11 (IL-11) receptor Lassen Therapeutics...
Items per page:
1 - 1 of 1